clinical trial · NCT05603832
A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement
Arthritis Innovation Corporation·phase3·completed·n = 151
Post Operative PainF140.25 % Bupivacaine HClAcetaminophenMethocarbamol
brief summary
This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.
started
Nov 17, 2022
primary completion
Nov 22, 2023
completion
Aug 23, 2024
last updated
Dec 18, 2025
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group Study of the Efficacy and Safety of a Single Administration of F14 for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Replacement
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol